[1]刘慧玲,赵恒伯,谢志勤,等.2022年江西省罕见病治疗费用核算分析 ——基于SHA2011[J].卫生经济研究,2025,42(02):46-50.
　LIU Huiling,ZHAO Hengbo,XIE Zhiqin,et al.Analysis of Rare Disease Treatment Cost Accounting in Jiangxi Province in 2022 ——Based on SHA2011[J].Journal Press of Health Economics Research,2025,42(02):46-50.
点击复制

2022年江西省罕见病治疗费用核算分析
——基于SHA2011
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年02期
页码:
46-50
栏目:
成本与费用
出版日期:
2025-02-06

文章信息/Info

Title:
Analysis of Rare Disease Treatment Cost Accounting in Jiangxi Province in 2022
——Based on SHA2011
作者:
刘慧玲1; 赵恒伯2; 谢志勤3; 吴海波1
1.江西中医药大学经济与管理学院，江西 南昌 330004
2.豫章师范学院，江西 南昌 330005
3.南昌大学第一附属医院，江西 南昌 330021
Author(s):
LIU Huiling;  ZHAO Hengbo;  XIE Zhiqin;  WU Haibo
School of Economics and Management, Jiangxi University of Chinese Medicine,Nanchang Jiangxi 330004, China
关键词:
罕见病; 治疗费用; 卫生费用核算体系2011; 江西省
Keywords:
rare diseases;  treatment cost;  health cost accounting system 2011;  Jiangxi Province
分类号:
R19
文献标志码:
A
摘要:
目的：分析2022年江西省罕见病治疗费用及其影响因素,为完善罕见病防治策略提供参考。方法：基于SHA2011理论和方法，核算分析2022年江西省罕见病治疗费用,采用K-Means聚类和支持向量机模型分析罕见病住院费用的影响因素。结果：2022年江西省罕见病治疗费用6 711.82万元，机构流向以综合医院、省级医院为主，患者分布以55~59岁和20岁以下年龄组为主，神经系统疾病所占费用最高，影响罕见病住院费用的最主要因素是实际住院天数和药占比。结论：加强罕见病药品研发与药品供应保障，优化老年、儿童及重点病种的罕见病治疗策略，提高基层罕见病诊疗能力，确保罕见病患者能够得到及时、有效的治疗。
Abstract:
Objective To analyze the cost of rare disease treatment and its influencing factors in Jiangxi Province in 2022, and to provide reference for improving the strategy of rare disease prevention and treatment. Methods Based on the theory and method of SHA2011, the treatment cost of rare diseases in Jiangxi Province in 2022 was analyzed, and the influencing factors of hospitalization cost of rare diseases were analyzed by K-Means clustering and support vector machine model. Results In 2022, the treatment cost of rare diseases in Jiangxi Province was 67.118 2 million yuan. the institutional flow was mainly in general hospitals and provincial hospitals, the distribution of patients was mainly in the age groups of 55-59 years old and under 20 years old, and neurological diseases accounted for the highest cost, and the most important factors affecting the cost of hospitalization for rare diseases were the actual hospitalization days and the proportion of drugs. Conclusion It is necessary to strengthen the research and development of rare disease drugs and drug supply guarantee, optimize the treatment strategy of rare disease for the elderly, children and key diseases, and improve the diagnosis and treatment capacity of rare disease at primary level, so as to ensure that patients with rare disease can receive timely and effective treatment.

参考文献/References:

[1] 王琳.中国罕见病定义研究报告[R].上海:上海市罕见病防治基金会，2021.
[2] Kirk L.The power of being counted[R].New York:RARE-X,2022.
[3] 李晓宏，彭训文，王文正.共享机遇 共创未来[N].人民日报海外报，2024-04-04（006）.
[4] 张倩，范文杰.推广“基因婚检”预防出生缺陷[N].人民政协报，2024-04-17（006）.
[5] 许滋靖.河北省罕见病治疗服务费用核算研究[D].唐山:华北理工大学，2023.
[6] 疼痛挑战基金会.罕见病调研报告[R].2018.
[7] 姚明宇，皮德常，丛湘香.基于k-means 的中文文本聚类算法[A].Proceedings of 2010 International Conference on Services Science,Management and Engineering （Volume2）[C].2010:20-23.
[8] 张青.江浙地区青年与成熟女性体型对比分析[D].杭州：浙江理工大学，2019.
[9] Vapnik V.统计学理论的本质[M].张学工，译.北京:清华大学出版社,2000:1-13.
[10] 郭小会，袁雪丹.基于救援规则的罕见病用药评价指标初探[J].中国医疗保险，2023（07）：97-103.
[11] 彭菲菲，蒋君好，鲍宇健，等.基于《第一批罕见病目录》的我国罕见病药物上市情况分析[J].中国药房，2024，35（11）：1291-1295.
[12] 詹洪春，潘锋.破解罕见病救治难题需统筹构建多层次保障机制[J].妇儿健康导刊，2023，3（07）：4-8.
[13] 康静，张赐，张正义.三级医院全科医学科中年住院患者慢性病共病分布及因素研究[J].中国全科医学，2024，27（11）：1310-1315.
[14] 江一帆，杜启霞，董琬月.社会交往对老年糖尿病健康管理效果的影响分析[J].中国农村卫生，2024，16（06）：51-54.
[15] 冯俊超，李顺平，房云海，等.全球血友病患者健康效用值的系统综述于Meta分析[J].中国药房，2023，34（24）：3012-3019.
[16] 许晨席，张心洁.镇江市罕见病患者用药保障中存在的问题研究[J].医学与社会，2024，37（03）：64-70.

相似文献/References:

[1]胡善联.国内外罕见病的保障政策研究[J].卫生经济研究,2018,(05):3.
[2]任杨玲,杨晓玮,沈 迟,等.陕西省不同年龄人群治疗费用分布研究——基于经常性卫生费用[J].卫生经济研究,2019,(02):46.
　REN Yang-ling,YANG Xiao-wei,SHEN Chi,et al.Study on the Distribution of Treatment Costs for Different Age Groups in Shaanxi Province——Based on Regular Health Costs[J].Journal Press of Health Economics Research,2019,(02):46.
[3]李 勇,王 冬,向国春,等.广东省恶性肿瘤治疗费用核算结果分析——基于“SHA2011”[J].卫生经济研究,2019,(09):25.
　LI Yong,WANG Dong,XIANG Guo-chun,et al.Analysis of Accounting Results of Treatment Costs for Malignant Tumors in Guangdong Province——Based on “SHA2011”[J].Journal Press of Health Economics Research,2019,(02):25.
[4]陈馨仪,符 晓,王安石,等.罕见病患者治疗及保障研究[J].卫生经济研究,2020,(09):40.
　CHEN Xin-yi,FU Xiao,WANG An-shi,et al.Research on the Treatment and Guarantee of Patients with Rare Diseases[J].Journal Press of Health Economics Research,2020,(02):40.
[5]董 辉,汤质如,严 训,等.安徽省恶性肿瘤治疗费用分析——基于“卫生费用核算体系2011”[J].卫生经济研究,2021,38(2):58.
　DONG Hui,TANG Zhi-ru,YAN Xun,et al.Analysis on Malignant Tumor Treatment Cost in Anhui Province——Based on the SHA 2011[J].Journal Press of Health Economics Research,2021,38(02):58.
[6]李 涛,柴培培,张毓辉,等.我国肿瘤治疗费用核算与筹资负担分析[J].卫生经济研究,2021,38(7):17.
　LI Tao,CHAI Pei-pei,ZHANG Yu-hui,et al.Analysis of Cost Accounting and Financing Burden of Tumor Treatment in China[J].Journal Press of Health Economics Research,2021,38(02):17.
[7]王子琪,闵连星,田兴军,等.我国罕见病医保政策的现状及优化路径[J].卫生经济研究,2021,38(11):22.
　WANG Zi-qi,MIN Lian-xing,TIAN Xing-jun,et al.The Situation and Optimization Path of Medical Insurance Policy for Rare Diseases in China[J].Journal Press of Health Economics Research,2021,38(02):22.
[8]李奕昊,唐贵忠.罕见病用药可负担性评价及医保政策研究[J].卫生经济研究,2022,39(4):53.
　LI Yi-hao,TANG Gui-zhong.Affordability Evaluation of Drugs for Rare Diseases and Research on Medical Insurance Policy[J].Journal Press of Health Economics Research,2022,39(02):53.
[9]陈春华,曹 勇,朱碧帆,等.2014—2018年上海市老年人治疗费用核算与分析——基于“卫生费用核算体系2011”[J].卫生经济研究,2022,39(5):27.
　CHEN Chun-hua,CAO Yong,ZHU Bi-fan,et al.Accounting and Analysis of Treatment Costs for the Elderly in Shanghai from 2014 to 2018 ——Based on "the System of Health Accounts 2011"[J].Journal Press of Health Economics Research,2022,39(02):27.
[10]张永理,张开然.我国罕见病患者医疗保障现状及改进建议[J].卫生经济研究,2023,40(1):53.
　ZHANG Yongli,ZHANG Kairan.Medical Security Status and Improvement Suggestions for Patients with Rare Diseases in China[J].Journal Press of Health Economics Research,2023,40(02):53.

更新日期/Last Update: 2025-02-06